Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
367
datasets available to search
ShareScore release 0.9.0
Dataset results
367 results for “Ibrutinib”
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
ClinicalTrials.gov study NCT04260217. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Ublituximab + Ibrutinib in Select B-cell Malignancies
ClinicalTrials.gov study NCT02013128. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
ClinicalTrials.gov study NCT03280160. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
ClinicalTrials.gov study NCT03015792. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
ClinicalTrials.gov study NCT03359460. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
ClinicalTrials.gov study NCT04739813. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
ClinicalTrials.gov study NCT03720561. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1
ClinicalTrials.gov study NCT06136559. IPD Sharing: YES. Countries: 29. Publications: 0.
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib
ClinicalTrials.gov study NCT02267590. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT03399513. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
ClinicalTrials.gov study NCT05998642. IPD Sharing: NO. Countries: 1. Publications: 0.
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
ClinicalTrials.gov study NCT02677948. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
ClinicalTrials.gov study NCT02991638. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
ClinicalTrials.gov study NCT02160015. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT04758975. IPD Sharing: NO. Countries: 1. Publications: 0.
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT06536049. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT01955499. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
ClinicalTrials.gov study NCT04263480. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
ClinicalTrials.gov study NCT07169565. IPD Sharing: NO. Countries: 0. Publications: 0.
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT02537613. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.